Corporate ActionNov 6, 2026, 05:26 PM
Mangoceuticals Approves Series D Preferred Stock Offering; Sets Annual Meeting
AI Summary
Mangoceuticals, Inc. announced that the sole holder of its Series B Convertible Preferred Stock has approved the terms of a new Series D Convertible Cumulative Preferred Stock and an amendment to the Series B Preferred Stock designation. The company plans to offer up to 1,000,000 shares of Series D Preferred Stock at $10.00 per share through a Regulation A offering. The Series B Amendment acknowledges the senior rights of the Series D Preferred Stock. Additionally, the company has set its combined 2025 and 2026 Annual Meeting for December 30, 2026, with a record date of November 12, 2026.
Key Highlights
- Mangoceuticals holder of Series B Preferred Stock approved Series D Preferred Stock terms and Series B Amendment.
- Company to offer up to 1,000,000 shares of Series D Preferred Stock at $10.00 per share via Regulation A offering.
- Series B Amendment recognizes senior dividend and liquidation rights of Series D Preferred Stock.
- Series D Preferred Stock and underlying common stock not registered under Securities Act.
- Combined 2025 and 2026 Annual Meeting scheduled for December 30, 2026.
- Record date for Annual Meeting set as November 12, 2026.
- Shareholder proposals for inclusion in proxy materials due by November 16, 2026.
Price Impact
More from MGRX